Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
boston blog main
boston top stories
life sciences
national blog main
national top stories
akcea therapeutics
alnylam pharmaceuticals
barry greene
biopharma
boston university
clinical trials
dan ollendorf
deals
drugs
duchenne
europe blog main
europe top stories
fda
hereditary transthyretin amyloidosis
inotersen
john berk
licensing
m&a
mary o'donnell
muscular dystrophy
new york blog main
new york top stories
patisiran
regeneron pharmaceuticals
rna interference
roche
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
sarepta therapeutics
tafamidis
the amyloidosis foundation
What
fda
2
×
historic
2
×
medicine
2
×
rna
2
×
ago
alnylam
approval
approve
awaits
betting
billion
biological
biopharma
crossed
deal
decades
decision
discovered
duchenne
fingers
friday
gene
patients
puts
recently
roche
sarepta
second
swiss
therapeutics
therapy
time
trick
uses
won
Language
unset
Current search:
rna
×
medicine
×
fda
×
historic
×
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision